Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Anthony David Elias

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone720/848-0347

    Collapse Research 
    Collapse research activities and funding
    P01CA038493     (ELIAS, ANTHONY D)Jul 1, 1985 - Nov 30, 1999
    NIH/NCI
    SOLID TUMOR AUTOLOGOUS MARROW PROGRAM
    Role: Principal Investigator

    U10CA042777     (ELIAS, ANTHONY D)Jan 1, 1988 - Dec 31, 2015
    NIH/NCI
    University of Colorado Southwest Oncology Group
    Role: Principal Investigator

    R21CA081324     (ELIAS, ANTHONY D)Apr 5, 1999 - Mar 31, 2003
    NIH/NCI
    MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
    Role: Principal Investigator

    U10CA180834     (ELIAS, ANTHONY D)Apr 14, 2014 - Feb 28, 2019
    NIH/NCI
    University of Colorado NTCN Lead Academic Participating Site (LAPS)
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2017 Sep 08. PMID: 28887726.
      View in: PubMed
    2. Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 Jul 01; 77(13):3455-3466. PMID: 28512248.
      View in: PubMed
    3. Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 Apr; 15(4):494-503. PMID: 28404760.
      View in: PubMed
    4. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 Apr; 15(4):433-451. PMID: 28404755.
      View in: PubMed
    5. Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70. PMID: 27987198.
      View in: PubMed
    6. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721. PMID: 27702820.
      View in: PubMed
    7. Villalobos VM, Hoffner B, Elias AD. We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas. Cancer. 2017 Jan 01; 123(1):20-24. PMID: 27696384.
      View in: PubMed
    8. Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 12. PMID: 27621408.
      View in: PubMed
    9. D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 Nov; 14(11):1054-1067. PMID: 27565181.
      View in: PubMed
    10. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    11. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    12. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97. PMID: 27291997.
      View in: PubMed
    13. Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol. 2016 Oct; 56:40-51. PMID: 27260947.
      View in: PubMed
    14. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016 Jul; 8(4):305-8. PMID: 27482289; PMCID: PMC4952024.
    15. Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 Jun 10; 34(17):1995-2002. PMID: 27001563; PMCID: PMC4966515 [Available on 04/10/17].
    16. Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016 Mar 15; 18(1):34. PMID: 26979312; PMCID: PMC4791863.
    17. Sedjo RL, Flatt SW, Byers T, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Wyatt H, Rock CL. Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Support Care Cancer. 2016 Aug; 24(8):3285-93. PMID: 26945570.
      View in: PubMed
    18. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54. PMID: 26957618.
      View in: PubMed
    19. Elias AD, Wang WS, Hardesty L. A 55-Year-Old Woman With New Triple-Negative Breast Mass, Less Than 2 cm on Both Mammogram and Ultrasound. Oncology (Williston Park). 2016 Mar; 30(3):258-62. PMID: 26984221.
      View in: PubMed
    20. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85. PMID: 26656517.
      View in: PubMed
    21. Demark-Wahnefried W, Colditz GA, Rock CL, Sedjo RL, Liu J, Wolin KY, Krontiras H, Byers T, Pakiz B, Parker BA, Naughton M, Elias A, Ganz PA. Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Res Treat. 2015 Nov; 154(2):329-37. PMID: 26518022; PMCID: PMC4654570 [Available on 11/01/16].
    22. Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep; 29(9):669-70, 678-9. PMID: 26384804.
      View in: PubMed
    23. Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. J Clin Oncol. 2015 Oct 01; 33(28):3169-76. PMID: 26282657; PMCID: PMC4582146 [Available on 10/01/16].
    24. Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015 Dec; 6(5-6):206-13. PMID: 26201402.
      View in: PubMed
    25. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75. PMID: 25870381.
      View in: PubMed
    26. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
    27. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar; 14(3):769-78. PMID: 25713333; PMCID: PMC4534304.
    28. Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF. Management of young breast cancer patients with de novo genetic mutations. Oncology (Williston Park). 2014 Oct; 28(10):895-6. PMID: 25323616.
      View in: PubMed
    29. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul; 16(7):1006-9. PMID: 24497407; PMCID: PMC4057140.
    30. Lopez JP, Gajdos C, Elias A. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun; 16(6):387. PMID: 24756367.
      View in: PubMed
    31. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90. PMID: 24717572.
      View in: PubMed
    32. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41. PMID: 24670685; PMCID: PMC4277862.
    33. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1):R7. PMID: 24451109; PMCID: PMC3978822.
    34. Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the aorta: a systematic review and pooled analysis of published reports. Ann Vasc Surg. 2014 Feb; 28(2):515-25. PMID: 24485779.
      View in: PubMed
    35. Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013 Oct; 22(5):650-6. PMID: 23958375.
      View in: PubMed
    36. Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013 Oct; 49(15):3219-28. PMID: 23835252.
      View in: PubMed
    37. Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun; 27(6):526-7, 566. PMID: 23909065.
      View in: PubMed
    38. Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. Contemp Clin Trials. 2013 Mar; 34(2):282-95. PMID: 23266440; PMCID: PMC3593786.
    39. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    40. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15; 1(1):16. PMID: 23369448; PMCID: PMC3560981.
    41. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32. PMID: 22821401; PMCID: PMC3818141.
    42. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer. 2012 Sep 01; 118(17):4098-104. PMID: 22281842.
      View in: PubMed
    43. Elias AD. Management of Small T1a/b N0 Breast Cancers. Am Soc Clin Oncol Educ Book. 2012; 10-9. PMID: 24451702.
      View in: PubMed
    44. Borges VF, Elias AD. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. J Clin Oncol. 2011 Aug 20; 29(24):3205-6. PMID: 21768457.
      View in: PubMed
    45. Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF. Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park). 2011 Apr 15; 25(4):351-6. PMID: 21618957.
      View in: PubMed
    46. Gajdos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol. 2011 Mar 16; 5:35-43. PMID: 21499557; PMCID: PMC3076042.
    47. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010 Dec; 33(6):637-45. PMID: 20023571.
      View in: PubMed
    48. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010 Dec; 1(6):306-19. PMID: 21761362; PMCID: PMC4561556.
    49. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55. PMID: 20665103; PMCID: PMC3851293.
    50. Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Clin Breast Cancer. 2010 Apr; 10(2):148-53. PMID: 20299319.
      View in: PubMed
    51. Weitzel LR, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Queensland KM, Singh M, Wischmeyer PE, Duncan MW, Elias A. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat. 2010 Nov; 124(2):297-305. PMID: 20087651.
      View in: PubMed
    52. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21. PMID: 19933919; PMCID: PMC2815711.
    53. Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91. PMID: 19777765.
      View in: PubMed
    54. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40. PMID: 19451436; PMCID: PMC2716936.
    55. Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer. Oncology (Williston Park). 2008 Oct; 22(11):1270-6. PMID: 18980024.
      View in: PubMed
    56. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. PMID: 18347007.
      View in: PubMed
    57. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501. PMID: 18338247.
      View in: PubMed
    58. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88. PMID: 18327671.
      View in: PubMed
    59. Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score. Oncology (Williston Park). 2007 Sep; 21(10):1212-7. PMID: 17926799.
      View in: PubMed
    60. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007 May 01; 25(13):1677-82. PMID: 17404368.
      View in: PubMed
    61. Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Elias A. A woman with primary breast cancer and a solitary sternal metastasis. Oncology (Williston Park). 2006 Aug; 20(9):1068-71, 1075, 1079-80. PMID: 16986350.
      View in: PubMed
    62. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006 May 15; 12(10):3124-9. PMID: 16707611.
      View in: PubMed
    63. Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology (Williston Park). 2005 Mar; 19(3):278, 283-4, 287 passim. PMID: 15828548.
      View in: PubMed
    64. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 2004; 6(2):93-101. PMID: 14979914; PMCID: PMC400664.
    65. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003 Feb; 77(3):245-52. PMID: 12602924.
      View in: PubMed
    66. Elias AD, Kumar P, Herndon J, Skarin AT, Sugarbaker DJ, Green MR. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clin Lung Cancer. 2002 Sep; 4(2):95-103. PMID: 14653865.
      View in: PubMed
    67. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. PMID: 12393437.
      View in: PubMed
    68. Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant. 2002; 8(6):326-33. PMID: 12108918.
      View in: PubMed
    69. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205. PMID: 12017145.
      View in: PubMed
    70. Rizzo JD, Elias AD, Stiff PJ, Lazarus HM, Zhang MJ, Oblon DJ, Pecora AL, Hale GA, Horowitz MM. Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant. 2002; 8(5):273-80. PMID: 12064365.
      View in: PubMed
    71. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant. 2001 Sep; 28(5):447-54. PMID: 11593317.
      View in: PubMed
    72. Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9. PMID: 11561781.
      View in: PubMed
    73. Salgia R, Harpole D, Herndon JE, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001 Mar-Apr; 21(2B):1241-6. PMID: 11396194.
      View in: PubMed
    74. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78. PMID: 11277174.
      View in: PubMed
    75. Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma. 2001 Feb; 40(5-6):499-509. PMID: 11426523.
      View in: PubMed
    76. Elias AD. High dose chemotherapy with stem cell rescue for breast cancer: current status and future directions. Breast Dis. 2001; 14:51-68. PMID: 15687636.
      View in: PubMed
    77. Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76. PMID: 10918427.
      View in: PubMed
    78. Kraeft SK, Sutherland R, Gravelin L, Hu GH, Ferland LH, Richardson P, Elias A, Chen LB. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res. 2000 Feb; 6(2):434-42. PMID: 10690521.
      View in: PubMed
    79. Anderson WF, Reeves JE, Elias A, Berkel H. Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer. 2000 Jan 01; 88(1):95-107. PMID: 10618611.
      View in: PubMed
    80. Frei E, Ara G, Teicher B, Bunnell C, Richardson P, Wheeler C, Tew K, Elias A. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46. PMID: 10663642.
      View in: PubMed
    81. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95. PMID: 11063377.
      View in: PubMed
    82. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest. 1999 Dec; 116(6 Suppl):531S-538S. PMID: 10619526.
      View in: PubMed
    83. Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45. PMID: 10556951.
      View in: PubMed
    84. Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41. PMID: 10537336.
      View in: PubMed
    85. Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol. 1999 Apr; 17(4):1175. PMID: 10561176.
      View in: PubMed
    86. Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998 Sep; 4(9):2027-37. PMID: 9748116.
      View in: PubMed
    87. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. PMID: 9680339.
      View in: PubMed
    88. Avigan D, Richardson P, Elias A, Demetri G, Shapiro M, Schnipper L, Wheeler C. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14. PMID: 9690531.
      View in: PubMed
    89. Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clin Cancer Res. 1998 Jun; 4(6):1443-9. PMID: 9626461.
      View in: PubMed
    90. Elias AD. High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol. 1998 Apr; 25(2 Suppl 4):19-23; discussion 45-8. PMID: 9578058.
      View in: PubMed
    91. Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998 Mar; 16(3):1000-7. PMID: 9508183.
      View in: PubMed
    92. Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15; 91(2):717-23. PMID: 9427731.
      View in: PubMed
    93. Elias A. Dose-intensive therapy in small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):101S-106S. PMID: 9438698.
      View in: PubMed
    94. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997 Oct; 112(4 Suppl):251S-258S. PMID: 9337299.
      View in: PubMed
    95. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PMID: 9331127.
      View in: PubMed
    96. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106. PMID: 9267670.
      View in: PubMed
    97. Elias AD. Future directions in lung cancer research and therapeutics. Hematol Oncol Clin North Am. 1997 Jun; 11(3):519-27. PMID: 9209908.
      View in: PubMed
    98. Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E, Sugarbaker DJ. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997 May; 17(1):147-61. PMID: 9194034.
      View in: PubMed
    99. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997 Feb; 15(2):674-83. PMID: 9053493.
      View in: PubMed
    100. Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34. PMID: 9053498.
      View in: PubMed
    101. Elias A. Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol. 1997; 40 Suppl:S64-9. PMID: 9272137.
      View in: PubMed
    102. Chen L, Pulsipher M, Chen D, Sieff C, Elias A, Fine HA, Kufe DW. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996 Dec 01; 98(11):2539-48. PMID: 8958216; PMCID: PMC507711.
    103. Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):179-94. PMID: 8953602.
      View in: PubMed
    104. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92. PMID: 8918496.
      View in: PubMed
    105. Webb IJ, Coral FS, Andersen JW, Elias AD, Finberg RW, Nadler LM, Ritz J, Anderson KC. Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 1996 Sep; 36(9):782-8. PMID: 8823450.
      View in: PubMed
    106. Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 1996 Jun 01; 77(11):2393-9. PMID: 8635112.
      View in: PubMed
    107. Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, Demetri GD, Anderson KC. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. Transfusion. 1996 Feb; 36(2):160-7. PMID: 8614968.
      View in: PubMed
    108. Lazarus HM, Elias AD. Autologous bone marrow and peripheral blood progenitor cell transplants in small cell lung cancer. Bone Marrow Transplant. 1996 Jan; 17(1):1-3. PMID: 8673040.
      View in: PubMed
    109. Benjamin RJ, Linsley L, Axelrod JD, Churchill WH, Sieff C, Shulman LN, Elias A, Ayash L, Malachowski ME, Uhl L, et al. The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high-dose chemotherapy support. Transfusion. 1995 Oct; 35(10):837-44. PMID: 7570914.
      View in: PubMed
    110. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug; 9(4):765-85. PMID: 7490240.
      View in: PubMed
    111. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9. PMID: 7636547.
      View in: PubMed
    112. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, et al. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):70-4. PMID: 7544029.
      View in: PubMed
    113. Elias AD. Dose-intensive therapy for small cell lung cancer. Chest. 1995 Jun; 107(6 Suppl):261S-266S. PMID: 7781403.
      View in: PubMed
    114. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 1995 Mar; 15(3):373-9. PMID: 7599561.
      View in: PubMed
    115. Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Antman K, Rosowsky A, Frel E, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36(4):345-51. PMID: 7628055.
      View in: PubMed
    116. Wright JE, Tretyakov O, Ayash LJ, Elias A, Rosowsky A, Frei E. Analysis of 4-hydroxycyclophosphamide in human blood. Anal Biochem. 1995 Jan 01; 224(1):154-8. PMID: 7710063.
      View in: PubMed
    117. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol. 1994 Oct; 21(5 Suppl 12):83-5. PMID: 7992072.
      View in: PubMed
    118. Elias AD. Salvage therapy for soft tissue sarcomas. Semin Oncol. 1994 Aug; 21(4 Suppl 7):76-81. PMID: 8091245.
      View in: PubMed
    119. Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, Lynch T, Levitt D, Resta D, Demetri G, et al. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol. 1994 Aug; 87(4):678-86. PMID: 7986706.
      View in: PubMed
    120. Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol. 1994 May; 87(1):153-61. PMID: 7947240.
      View in: PubMed
    121. Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer. 1994 Feb 15; 73(4):1171-6. PMID: 8313319.
      View in: PubMed
    122. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Feb; 12(2):347-52. PMID: 8113842.
      View in: PubMed
    123. Elias AD, Skarin AT, Gonin R, Oliynyk P, Stomper PC, O'Hara C, Socinski MA, Sheldon T, Maggs P, Frei E. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol. 1994 Feb; 17(1):26-36. PMID: 8311004.
      View in: PubMed
    124. Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr. 1994; (16):91-4. PMID: 7528031.
      View in: PubMed
    125. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994 Jan; 12(1):37-44. PMID: 7505807.
      View in: PubMed
    126. Kirn DH, Lynch TJ, Mentzer SJ, Lee TH, Strauss GM, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. J Thorac Cardiovasc Surg. 1993 Oct; 106(4):696-702. PMID: 8412265.
      View in: PubMed
    127. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85. PMID: 8315425.
      View in: PubMed
    128. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. PMID: 8099120.
      View in: PubMed
    129. Lynch TJ, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E. Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. Cancer. 1993 May 15; 71(10):2953-7. PMID: 8387871.
      View in: PubMed
    130. Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993 Apr 07; 85(7):559-66. PMID: 8384264.
      View in: PubMed
    131. Elias A. Chemotherapy and radiotherapy for regionally advanced non-small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):362S-366S. PMID: 8384971.
      View in: PubMed
    132. Elias AD, Ayash L, Skarin AT, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper L, Frei E, Antman KH. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):433S-435S. PMID: 8096454.
      View in: PubMed
    133. Elias AD. Chemotherapy for soft-tissue sarcomas. Clin Orthop Relat Res. 1993 Apr; (289):94-105. PMID: 8472436.
      View in: PubMed
    134. Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E, Antman K. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother. 1993; 2(3):377-82. PMID: 7522891.
      View in: PubMed
    135. Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother. 1993; 2(4):507-11. PMID: 7916250.
      View in: PubMed
    136. Lynch TJ, Clark JR, Kalish LA, Fallon BG, Elias AD, Skarin A, Frei E. Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer. Cancer. 1992 Oct 01; 70(7):1880-5. PMID: 1326396.
      View in: PubMed
    137. Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JA, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med. 1992 Sep; 33(9):1594-9. PMID: 1517831.
      View in: PubMed
    138. Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1992 Aug; 4(4):681-8. PMID: 1511024.
      View in: PubMed
    139. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992 Jul; 10(1):57-63. PMID: 1515880.
      View in: PubMed
    140. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992 Jun; 10(6):995-1000. PMID: 1588381.
      View in: PubMed
    141. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992 Jun 01; 79(11):3036-44. PMID: 1350229.
      View in: PubMed
    142. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol. 1992 May; 10(5):829-38. PMID: 1314892.
      View in: PubMed
    143. Elias AD. The clinical management of soft tissue sarcomas. Semin Oncol. 1992 Feb; 19(1 Suppl 1):19-25. PMID: 1411616.
      View in: PubMed
    144. Elias AD. Future directions in the management of soft tissue sarcomas. Hematol Oncol. 1992 Jan-Feb; 10(1):53-60. PMID: 1563704.
      View in: PubMed
    145. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan; 10(1):102-10. PMID: 1727912.
      View in: PubMed
    146. Elias AD, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Pelaez J, Hunt M, et al. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S25-9. PMID: 1687204.
      View in: PubMed
    147. Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1991 Aug; 3(4):671-6. PMID: 1932226.
      View in: PubMed
    148. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb; 9(2):320-7. PMID: 1846407.
      View in: PubMed
    149. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E, et al. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. J Cancer Res Clin Oncol. 1991; 117 Suppl 4:S208-13. PMID: 1795009.
      View in: PubMed
    150. Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol. 1991; 29(1):61-5. PMID: 1742850.
      View in: PubMed
    151. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706. PMID: 2213105.
      View in: PubMed
    152. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul; 8(7):1239-45. PMID: 2162912.
      View in: PubMed
    153. Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1990 Jun; 2(3):474-80. PMID: 2092763.
      View in: PubMed
    154. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73. PMID: 2110386.
      View in: PubMed
    155. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990 Apr; 17(2 Suppl 4):41-9. PMID: 2110385.
      View in: PubMed
    156. Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res. 1990 Feb 15; 50(4):1170-5. PMID: 2404589.
      View in: PubMed
    157. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol. 1990 Feb; 17(1 Suppl 2):7-15. PMID: 2106162.
      View in: PubMed
    158. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol. 1990 Feb; 17(1 Suppl 3):33-8. PMID: 2106166.
      View in: PubMed
    159. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan; 8(1):170-8. PMID: 2104923.
      View in: PubMed
    160. Elias AD, Pap SA, Bernal SD. Purging of small cell lung cancer-contaminated bone marrow by monoclonal antibodies and magnetic beads. Prog Clin Biol Res. 1990; 333:263-75. PMID: 2155434.
      View in: PubMed
    161. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep; 7(9):1208-16. PMID: 2504890.
      View in: PubMed
    162. Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol. 1989 Aug; 16(4):305-11. PMID: 2667145.
      View in: PubMed
    163. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May; 7(5):651-61. PMID: 2651580.
      View in: PubMed
    164. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31. PMID: 2491883.
      View in: PubMed
    165. Bernal SD, Elias AD. Early lung cancer detection: monoclonal antibody staining of exfoliated cells in sputum. J Clin Oncol. 1988 Nov; 6(11):1676-8. PMID: 2460593.
      View in: PubMed
    166. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst. 1988 Oct 05; 80(15):1221-6. PMID: 3138431.
      View in: PubMed
    167. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8. PMID: 3045544.
      View in: PubMed
    168. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7. PMID: 3042045.
      View in: PubMed
    169. Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol. 1988 Jun; 124(6):878-84. PMID: 3288124.
      View in: PubMed
    170. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009.
      View in: PubMed
    171. Elias AD, Cohen BF, Bernal SD. Keratin subtypes of small cell lung cancer. Cancer Res. 1988 May 15; 48(10):2724-9. PMID: 2452011.
      View in: PubMed
    172. Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988; 4(1):53-8. PMID: 3281212.
      View in: PubMed
    173. Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65. PMID: 3281213.
      View in: PubMed
    174. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep. 1987 Nov; 71(11):1043-7. PMID: 3119200.
      View in: PubMed
    175. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7. PMID: 3534155.
      View in: PubMed
    176. Elias AD, Antman KH. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. Cancer Treat Rep. 1986 Jul; 70(7):827-33. PMID: 3087617.
      View in: PubMed
    177. Elias AD, Elias ER. Matching of couples in the NRMP. N Engl J Med. 1980 Jun 19; 302(25):1425-6. PMID: 7374708.
      View in: PubMed
    Elias's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)